文献速递胸部肿瘤

KRAS:肺癌治疗乐观的理由

KRAS: Reasons for optimism in lung cancer.
PubMed 文献 · Eur J Cancer · 2018-06-09

本文是一篇叙述性综述,以SELECT-1 III期试验等历史失败为背景,讨论KRAS突变非小细胞肺癌(NSCLC)靶向治疗的挫折与前景。文章指出突变亚型(最常见G12C)比KRAS突变存在与否更具相关性,多种直接靶向这些亚型的小分子正在开发中并显示 promising 生物活性。

要点

  • KRAS突变作为预后和预测生物标志物的潜力有限。
  • 突变亚型(如G12C)比单纯KRAS突变状态更具临床相关性。
  • 直接靶向KRAS亚型的小分子正在开发,部分处于临床前验证后期。

核心结论

  • KRAS突变亚型(最常见G12C)比KRAS突变存在与否更具相关性。
  • 直接靶向KRAS突变亚型的小分子在研并显示 promising 生物活性。

研究设计与样本

  • 叙述性综述,以SELECT-1 III期试验等历史失败为背景。

主要发现

  • SELECT-1 III期试验结果加入了靶向KRAS突变疾病的历史和当代失望之列。
  • 既往失败包括法尼基转移酶抑制和合成致死伙伴如STK33。
  • 多种直接靶向KRAS突变亚型的小分子正在开发,部分处于临床前验证后期。

临床怎么用

  • 对NSCLC进行KRAS突变亚型(如G12C)检测可能比仅检测KRAS突变状态更有意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite being the most frequent gain-of-function genetic alteration in human cancer, KRAS mutation has to date offered only limited potential as a prognostic and predictive biomarker. Results from the phase III SELECT-1 trial in non-small cell lung cancer (NSCLC) recently added to a number of historical and more contemporary disappointments in targeting KRAS mutant disease, including farnesyl transferase inhibition and synthetic lethality partners such as STK33. This narrative review uses the context of these previous failures to demonstrate how the knowledge gained from these experiences can be used as a platform for exciting advances in NSCLC on the horizon. It now seems clear that mutational subtype (most commonly G12C) of individual mutations is of greater relevance than the categorical evaluation of KRAS mutation presence or otherwise. A number of direct small molecules targeted to these subtypes are in development and have shown promising biological activity, with some in the late stages of preclinical validation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lindsay CR, Jamal-Hanjani M, Forster M, et al. KRAS: Reasons for optimism in lung cancer. Eur J Cancer. 2018. PMID: 29894909. doi:10.1016/j.ejca.2018.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。